Adverse events in clinical trials: is a new approach needed?

The Lancet

Volumn 372, Issue 9638, 2008, Pages 535-536

  Barrios, Vivencio ^a   Escobar, Carlos ^b   Prieto, Luis ^c   Herranz, Inmaculada ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG; RAMIPRIL; TELMISARTAN;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG WITHDRAWAL; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LETTER; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 49149128437     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61232-5     Document Type: Letter

References (3)

1. Stone G.W., White H.D., Ohman E.M., et al., for the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
2. Ho P.M., Magid D.J., Shetterly S.M., et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 168 (2008) 271-276
3. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559